0001437749-24-018624.txt : 20240529
0001437749-24-018624.hdr.sgml : 20240529
20240529175818
ACCESSION NUMBER: 0001437749-24-018624
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240524
FILED AS OF DATE: 20240529
DATE AS OF CHANGE: 20240529
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lorrain Daniel S.
CENTRAL INDEX KEY: 0001861550
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-42001
FILM NUMBER: 241000011
MAIL ADDRESS:
STREET 1: 10578 SCIENCE CENTER DRIVE, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Contineum Therapeutics, Inc.
CENTRAL INDEX KEY: 0001855175
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 271467257
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10578 SCIENCE CENTER DRIVE, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: (858) 333-5280
MAIL ADDRESS:
STREET 1: 10578 SCIENCE CENTER DRIVE, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: Pipeline Therapeutics, Inc.
DATE OF NAME CHANGE: 20210405
4
1
rdgdoc.xml
OPTION GRANT
X0508
4
2024-05-24
0001855175
Contineum Therapeutics, Inc.
CTNM
0001861550
Lorrain Daniel S.
10578 SCIENCE CENTER DRIVE, SUITE 200
SAN DIEGO
CA
92121
1
Chief Scientific Officer
0
Stock Option (right to buy)
15.76
2024-05-24
4
A
0
100000
0
A
2034-05-23
Class A Common Stock
100000
100000
D
Stock Option (right to buy)
15.76
2024-05-24
4
A
0
3700
0
A
2034-05-23
Class A Common Stock
3700
3700
I
By Spouse
Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"). 25% of the option shares vest on April 5, 2025, and the remainder vests in equal monthly installments over the next 36 months thereafter, subject to the Reporting Person's continuous service.
Options granted under the Plan. 25% of the option shares vest on April 5, 2025, and the remainder vests in equal monthly installments over the next 36 months thereafter, subject to the Reporting Person's spouse's continuous service.
/s/ Peter Slover, Attorney-in-Fact
2024-05-29